Colorectal adenocarcinoma‐derived EGFR mutants are oncogenic and sensitive to EGFR‐targeted monoclonal antibodies, cetuximab and panitumumab
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Cancer"
DOI: 10.1002/ijc.32499
Abstract: Somatic mutations of epidermal growth factor receptor (EGFR) occur in ~3% of colorectal cancer (CRC) patients. Here, through systematic functional screening of 21 recurrent EGFR mutations selected from public data sets, we show that 11… read more here.
Keywords: derived egfr; egfr; egfr mutants; adenocarcinoma derived ... See more keywords
A comparison of panitumumab and cetuximab in the treatment of KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2022 at "Immunopharmacology and Immunotoxicology"
DOI: 10.1080/08923973.2022.2112222
Abstract: Abstract Aim Cetuximab and panitumumab are common antibodies against epidermal growth factor receptor (EGFR) that can be used in combination with chemotherapy for the treatment of metastatic colorectal cancer (mCRC). Although these two drugs are… read more here.
Keywords: arm; cetuximab; analysis; panitumumab ... See more keywords
The effectiveness of cetuximab and panitumumab when combined with FOLFIRI in second-line treatment of KRAS wild type metastatic colorectal cancers. Single centre experience
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Chemotherapy"
DOI: 10.1080/1120009x.2020.1861531
Abstract: Panitumumab and cetuximab are monoclonal antibodies known to be effective in metastatic colorectal cancer (mCRC). Although the survival benefits when combined with chemotherapy have been determined, there are no studies comparing the two agents with… read more here.
Keywords: second line; panitumumab; line treatment; cetuximab panitumumab ... See more keywords